Abd Allah E, et al. - In this randomized controlled trial with adult patients undergoing cardiac valve replacement surgery (n=64), researchers assessed the role of prophylactic high-dose atorvastatin for prevention of postoperative atrial fibrillation (POAF), inflammatory response reduction, and myocardial protection. Two groups with equal participants were defined. They administered 80 mg of atorvastatin (oral tablets), 12 and 2 hours preoperatively, and on the 2nd, 3rd, 4th, and 5th postoperative days in Group S. They administered placebo at the same time periods in the control group C. In adult patients undergoing isolated rheumatic cardiac valve replacement surgery, reduction in the incidence of POAF as well as in the inflammatory process can be achieved with prophylactic use of high dose atorvastatin, as concluded in this study.